SOURCE: Equity News Circuit

Equity News Circuit

May 01, 2013 08:45 ET

Free Research Reports on DDD, ESRX, NBS and TTHI Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 1, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

3D Systems Corporation (NYSE: DDD) shares spiked 6.91 percent on volume of over 9.0 million shares traded Tuesday to close at $38.24 a share. A 61 percent increase in printers' and other products sales drove revenues up 31 percent year-over-year to $102.1 million for the first quarter of 2013.

Find out more about 3D Systems including full access to the free equity report at: www.BedfordReport.com/DDD

Express Scripts Holding Company (NASDAQ: ESRX) shares gained 1.59 percent on volume of 11.51 million shares traded to close at $59.37 a share. The company reported adjusted earnings of $0.99 per share for the first quarter of 2013, an increase of 35.6 percent when compared to the year ago quarter.

Find out more about Express Scripts including full access to the free equity report at: www.BedfordReport.com/ESRX

NeoStem Inc. (NYSE: NBS) shares plunged 20.63 percent on volume of over 12.28 million shares traded to close at $0.50 a share. The company announced the pricing of a public offering of 20 million shares of common stock at a price of $0.50 per share. NeoStem is a provider of adult stem cell collection, processing and storage services in the United States.

Find out more about NeoStem including full access to the free equity report at: www.BedfordReport.com/NBS

Transition Therapeutics Inc. (NASDAQ: TTHI)(TSX: TTH) shares soared 37.78 percent on volume of 2.41 million shares traded to close at $3.10 a share. The company announced results from a five-week proof of concept clinical study of its type 2 diabetes drug, TT-401, showed "significant improvements in glycemic control and reductions in body weight."

Find out more about Transition Therapeutics including full access to the free equity report at: www.BedfordReport.com/TTHI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information